The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin

  • Hany Mohamed Khattab
  • Satoshi Kubota
  • Masaharu Takigawa
  • Takuo Kuboki
  • Walter Sebald
Review Article


The antagonist-specific regulation in tissue engineering constitutes important attempts to achieve an improved and rapid bone regeneration by controlling the natural biological response of the natural body growth factors. L51P is molecularly engineered bone morphogentic protein-2 (BMP-2) variant with a substitution of the 51st leucine with a proline residue. L51P is deficient in BMP receptor binding, but maintains its structure and affinity for inhibitory proteins such as noggin, chordin, and gremlin. These modifications convert the BMP-2 variant L51P into a receptor-inactive inhibitor of BMP antagonists. This current approach may prevent the uncontrolled bone overgrowth using high concentration of BMPs and thus regulates the possible growth factor’s high-dose side effects. Exploring of L51P biological functions is required to broad our understanding of BMP mutant biological functions and their potential clinical applications. The progress of L51P researches would hopefully lead to the development of multiple applications for using the L51P in bone and fracture healing disorders.


BMP-2 BMP antagonist L51P BMP negative feedback 



Bone morphogenetic protein


BMP receptor type I


BMP receptor type II


Cysteine-rich 61, connective tissue growth factor, nephroblastoma-overexpressed



The author would like to thank all his colleagues in the Department of Oral Rehabilitation and Regenerative Medicine, the Department of Biochemistry and Molecular Dentistry, and the Department of Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, for their generous hosting and all kind assistances during the time taken to accomplish this review. The author also would like to thank Dr. Kristin Sainani A. Professor at Stanford University for her technical assistance.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.


  1. 1.
    Sieber C, Kopf J, Hiepen C, Knaus P (2009) Recent advances in BMP receptor signaling (in eng). Cytokine Growth Factor Rev 20:343–355. CrossRefPubMedGoogle Scholar
  2. 2.
    Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments (in eng). Nat Med 19:179–192. CrossRefPubMedGoogle Scholar
  3. 3.
    Lorda-Diez CI, Montero JA, Rodriguez-Leon J, Garcia-Porrero JA, Hurle JM (2013) Expression and functional study of extracellular BMP antagonists during the morphogenesis of the digits and their associated connective tissues (in eng). PLoS One 8:e60423. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yanagita M (2005) BMP antagonists: their roles in development and involvement in pathophysiology (in eng). Cytokine Growth Factor Rev 16:309–317. CrossRefPubMedGoogle Scholar
  5. 5.
    Fajardo M, Liu CJ, Egol K (2009) Levels of expression for BMP-7 and several BMP antagonists may play an integral role in a fracture nonunion: a pilot study (in eng). Clin Orthop Relat Res 467:3071–3078. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zara JN, Siu RK, Zhang X, Shen J, Ngo R, Lee M, Li W, Chiang M, Chung J, Kwak J, Wu BM, Ting K, Soo C (2011) High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo (in eng). Tissue Eng Part A 17:1389–1399. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, Song F (2007) Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review (in eng). Health Technol Assess (Winchester, England) 11:1–150, iii-ivGoogle Scholar
  8. 8.
    Tsialogiannis E, Polyzois I, Oak Tang Q, Pavlou G, Tsiridis E, Heliotis M, Tsiridis E (2009) Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism (in eng). Expert Opin Ther Targets 13:123–137. CrossRefPubMedGoogle Scholar
  9. 9.
    Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD (2004) Molecular recognition of BMP-2 and BMP receptor IA (in eng). Nat Struct Mol Biol 11:481–488. CrossRefPubMedGoogle Scholar
  10. 10.
    Sebald W, Nickel J, Zhang JL, Mueller TD (2004) Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction (in eng). Biol Chem 385:697–710. CrossRefPubMedGoogle Scholar
  11. 11.
    Liu A, Niswander LA (2005) Bone morphogenetic protein signalling and vertebrate nervous system development (in eng). Nat Rev Neurosci 6:945–954. CrossRefPubMedGoogle Scholar
  12. 12.
    Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned (in eng). Spine J 11:471–491. CrossRefPubMedGoogle Scholar
  13. 13.
    McDonald IK, Thornton JM (1994) Satisfying hydrogen bonding potential in proteins (in eng). J Mol Biol 238:777–793. CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang JL, Huang Y, Qiu LY, Nickel J, Sebald W (2007) von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms (in eng). J Biol Chem 282:20002–20014. CrossRefPubMedGoogle Scholar
  15. 15.
    Albers CE, Hofstetter W, Sebald HJ, Sebald W, Siebenrock KA, Klenke FM (2012) L51P—A BMP2 variant with osteoinductive activity via inhibition of Noggin (in eng). Bone 51:401–406. CrossRefPubMedGoogle Scholar
  16. 16.
    Sebald HJ, Klenke FM, Siegrist M, Albers CE, Sebald W, Hofstetter W (2012) Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing (in eng). Acta Biomater 8:3816–3820. CrossRefPubMedGoogle Scholar
  17. 17.
    Khattab HM, Ono M, Sonoyama W, Oida Y, Shinkawa S, Yoshioka Y, Maekawa K, Tabata Y, Sugama K, Sebald W, Kuboki T (2014) The BMP2 antagonist inhibitor L51P enhances the osteogenic potential of BMP2 by simultaneous and delayed synergism (in eng). Bone 69:165–173. CrossRefPubMedGoogle Scholar
  18. 18.
    Tekari A, May RD, Frauchiger DA, Chan SC, Benneker LM, Gantenbein B (2017) The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells (in eng). Eur Cells Mater 33:197–210. CrossRefGoogle Scholar
  19. 19.
    Alberts B (2010) Cell biology: the endless frontier (in eng). Mol Biol Cell 21:3785. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    ten Dijke P (2006) Bone morphogenetic protein signal transduction in bone (in eng). Curr Med Res Opin 22:S7–S11. CrossRefPubMedGoogle Scholar
  21. 21.
    Chen G, Deng C, Li YP (2012) TGF-beta and BMP signaling in osteoblast differentiation and bone formation (in eng). Int J Biol Sci 8:272–288. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rosen V (2009) BMP2 signaling in bone development and repair (in eng). Cytokine Growth Factor Rev 20:475–480. CrossRefPubMedGoogle Scholar
  23. 23.
    Huang RL, Yuan Y, Tu J, Zou GM, Li Q (2014) Opposing TNF-alpha/IL-1beta- and BMP-2-activated MAPK signaling pathways converge on Runx2 to regulate BMP-2-induced osteoblastic differentiation (in eng). Cell Death Dis 5:e1187. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hassel S, Schmitt S, Hartung A, Roth M, Nohe A, Petersen N, Ehrlich M, Henis YI, Sebald W, Knaus P (2003) Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes (in eng). J Bone Jt Surg 85-A:44–51CrossRefGoogle Scholar
  25. 25.
    Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T (2000) BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6 (in eng). J Biol Chem 275:17647–17652. CrossRefPubMedGoogle Scholar
  26. 26.
    Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S (2001) Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells (in eng). Bone 28:491–498CrossRefPubMedGoogle Scholar
  27. 27.
    Vinals F, Lopez-Rovira T, Rosa JL, Ventura F (2002) Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2 (in eng). FEBS Lett 510:99–104CrossRefPubMedGoogle Scholar
  28. 28.
    Yamamoto M, Takahashi Y, Tabata Y (2003) Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein (in eng). Biomaterials 24:4375–4383CrossRefPubMedGoogle Scholar
  29. 29.
    Montjovent MO, Siegrist M, Klenke F, Wetterwald A, Dolder S, Hofstetter W (2013) Expression of antagonists of WNT and BMP signaling after non-rigid fixation of osteotomies (in eng). Bone 53:79–86. CrossRefPubMedGoogle Scholar
  30. 30.
    Wu M, Chen G, Li YP (2016) TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease (in eng). Bone Res 4:16009. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Minamizato T, Sakamoto K, Liu T, Kokubo H, Katsube K, Perbal B, Nakamura S, Yamaguchi A (2007) CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways (in eng). Biochem Biophys Res Commun 354:567–573. CrossRefPubMedGoogle Scholar
  32. 32.
    Matsushita Y, Sakamoto K, Tamamura Y, Shibata Y, Minamizato T, Kihara T, Ito M, Katsube K, Hiraoka S, Koseki H, Harada K, Yamaguchi A (2013) CCN3 protein participates in bone regeneration as an inhibitory factor (in eng). J Biol Chem 288:19973–19985. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Katsuki Y, Sakamoto K, Minamizato T, Makino H, Umezawa A, Ikeda MA, Perbal B, Amagasa T, Yamaguchi A, Katsube K (2008) Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1 (in eng). Biochem Biophys Res Commun 368:808–814. CrossRefPubMedGoogle Scholar
  34. 34.
    Yamaguchi A, Sakamoto K, Minamizato T, Katsube K, Nakanishi S (2008) Regulation of osteoblast differentiation mediated by BMP, Notch, and CCN3/NOV. Jpn Dental Sci Rev 44:48–56. CrossRefGoogle Scholar
  35. 35.
    Wang Y, Hong S, Li M, Zhang J, Bi Y et al (2013) Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells (in eng). J Orthop Res 31:1796–1803. PubMedGoogle Scholar
  36. 36.
    Song K, Krause C, Shi S, Patterson M, Suto R, Grgurevic L, Vukicevic S, van Dinther M, Falb D, Ten Dijke P, Alaoui-Ismaili MH (2010) Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity (in eng). J Biol Chem 285:12169–12180. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Seemann P, Brehm A, Konig J, Reissner C, Stricker S et al (2009) Mutations in GDF5 reveal a key residue mediating BMP inhibition by NOGGIN (in eng). PLoS Genet 5:e1000747. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Khattab HM, Aoyama E, Kubota S, Takigawa M (2015) Physical interaction of CCN2 with diverse growth factors involved in chondrocyte differentiation during endochondral ossification (in eng). J Cell Commun Signal 9:247–254. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Abreu JG, Ketpura NI, Reversade B, De Robertis EM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta (in eng). Nat Cell Biol 4:599–604. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Maeda A, Nishida T, Aoyama E, Kubota S, Lyons KM, Kuboki T, Takigawa M (2009) CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes (in eng). J Biochem 145:207–216. CrossRefPubMedGoogle Scholar
  41. 41.
    Aoyama E, Kubota S, Khattab HM, Nishida T, Takigawa M (2015) CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG (in eng). Bone 73:242–248. CrossRefPubMedGoogle Scholar
  42. 42.
    Takigawa M (2017) An early history of CCN2/CTGF research: the road to CCN2 via hcs24, ctgf, ecogenin, and regenerin (in eng). J Cell Commun Signal. Google Scholar
  43. 43.
    Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Canalis E (2008) Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia (in eng). Endocrinology 149:4374–4381. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Mundy C, Gannon M, Popoff SN (2014) Connective tissue growth factor (CTGF/CCN2) negatively regulates BMP-2 induced osteoblast differentiation and signaling (in eng). J Cell Physiol 229:672–681. CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Smerdel-Ramoya A, Zanotti S, Deregowski V, Canalis E (2008) Connective tissue growth factor enhances osteoblastogenesis in vitro (in eng). J Biol Chem 283:22690–22699. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Safadi FF, Xu J, Smock SL, Kanaan RA, Selim AH, Odgren PR, Marks SC Jr, Owen TA, Popoff SN (2003) Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo (in eng). J Cell Physiol 196:51–62. CrossRefPubMedGoogle Scholar
  47. 47.
    Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response (in eng). FASEB J 18:816–827. CrossRefPubMedGoogle Scholar
  48. 48.
    Leask A, Denton CP, Abraham DJ (2004) Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma (in eng). J Invest Dermatol 122:1–6. CrossRefPubMedGoogle Scholar
  49. 49.
    Grotendorst GR (1997) Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts (in eng). Cytokine Growth Factor Rev 8:171–179CrossRefPubMedGoogle Scholar
  50. 50.
    Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling (in eng). J Biol Chem 276:10594–10601. CrossRefPubMedGoogle Scholar
  51. 51.
    Daans M, Lories RJ, Luyten FP (2008) Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease (in eng). Arthritis Res Ther 10:R115. CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, Ceuppens JL, Luyten FP (2006) Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis (in eng). Arthritis Rheum 54:1736–1746. CrossRefPubMedGoogle Scholar
  53. 53.
    Komatsu M, Nakamura Y, Maruyama M, Abe K, Watanapokasin R, Kato H (2015) Expression profiles of human CCN genes in patients with osteoarthritis or rheumatoid arthritis (in eng). J Orthop Sci 20:708–716. CrossRefPubMedGoogle Scholar
  54. 54.
    Balemans W, Ebeling M, Patel N, Van Hul E, Olson P et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) (in eng). Hum Mol Genet 10:537–543CrossRefPubMedGoogle Scholar
  55. 55.
    Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein (in eng). Am J Hum Genet 68:577–589CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity (in eng). J Biol Chem 278:24113–24117. CrossRefPubMedGoogle Scholar
  57. 57.
    van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist (in eng). J Exp Med 199:805–814. CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist (in eng). EMBO J 22:6267–6276. CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA (2004) Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts (in eng). Bone 35:448–454. CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Prosthodontics, Faculty of Oral and Dental MedicineFayoum UniversityFayoumEgypt
  2. 2.Advanced Research Center for Oral and Craniofacial SciencesOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  3. 3.Department of Biochemistry and Molecular DentistryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  4. 4.Department of Oral Rehabilitation and Regenerative MedicineOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  5. 5.Physiological Chemistry IITheodor-Boveri-Institute for Biocenter of Würzburg UniversityWürzburgGermany

Personalised recommendations